Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
77.47
-0.46 (-0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...
Via
Benzinga
Exposures
Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
October 03, 2024
AstraZeneca's Calquence receives FDA Priority Review for previously untreated mantle cell lymphoma, showing promising Phase 3 trial results in reducing disease progression by 27%. An FDA decision is...
Via
Benzinga
Exposures
Product Safety
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
AstraZeneca Options Trading: A Deep Dive into Market Sentiment
September 05, 2024
Via
Benzinga
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
October 01, 2024
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via
News Direct
Is Summit Therapeutics Stock a Buy?
September 30, 2024
Its alliance with a successful foreign biotech could be decisive for the stock.
Via
The Motley Fool
Week In Review: Zenas Raises $259 Million In IPO
September 28, 2024
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Top Stock Reports For Toyota, AstraZeneca & Chubb
September 26, 2024
Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp., AstraZeneca PLC, and Chubb Ltd., as well as two micro-cap stocks Air T, Inc. and Preformed Line...
Via
Talk Markets
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
September 26, 2024
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, showcasing significant improvements in progression-free survival rates.
Via
Benzinga
Exposures
Product Safety
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
September 23, 2024
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...
Via
Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
September 23, 2024
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.
Via
Investor's Business Daily
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free...
Via
Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
September 19, 2024
For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the...
Via
Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.
Via
Benzinga
Exposures
Product Safety
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
September 12, 2024
The company says it's investment in R&D has paid off. Now, it needs to move its focus to launching new products.
Via
Investor's Business Daily
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
September 10, 2024
Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug imports. CEO Pascal Soriot assures compliance with Chinese regulations and...
Via
Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to...
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...
Via
Benzinga
3 Market-Beating Stocks to Buy for Less Than $100
September 06, 2024
These stocks are all up more than 20% this year.
Via
The Motley Fool
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities
September 05, 2024
Chinese police detain AstraZeneca employees over alleged data privacy breaches and unlicensed drug imports amid an anti-corruption drive.
Via
Benzinga
Topics
Law Enforcement
Exposures
Legal
Reasonable Growth, Debt Levels, and a High ROIC Make ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Appealing to Quality Investors.
September 04, 2024
Why ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Deserves Consideration as a Quality Investment.
Via
Chartmill
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
September 04, 2024
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is...
Via
Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Via
Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
August 23, 2024
AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.